Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAM-001 in Adults With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT05798923Phase 2Recruiting
- Sponsor
- IRulya Therapeutics
- Start
- Aug 2023
- Primary completion
- Mar 2028
- Modality
- Inhalation Devices, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of LAM-001 in Pulmonary Hypertension Due To Interstitial Lung Disease (PH-ILD), sponsored by IRulya Therapeutics. Started Aug 2023; status: recruiting.
02
Drugs
LAM-001
03
Conditions
Pulmonary Hypertension Due To Interstitial Lung Disease (PH-ILD)
Beyond the preview
Go deeper on NCT05798923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05798923.